Company
Nuvation
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
1
1 still marketed
Novel approvals
1
Approvals since 2021
2
Originals and new uses
Phase 3 trials
4
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
- Phase 110
Recent approvals
Originals and efficacy supplements, newest first.
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
- SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)Pivotal-lookingRecruiting
Nuvation Bio Inc.Industry
NCT05303519 · 365 participants (planned) · Start Jun 5, 2023 · Primary completion Dec 1, 2028
Drug: safusidenib; Placebo · For: Glioma; Astrocytoma, Grade IV; IDH1-mutant Glioma and 5 more
Sites: Birmingham, Alabama; Phoenix, Arizona; La Jolla, California · 75 sites in all
- A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer PatientsPivotal-lookingRecruiting
Nuvation Bio Inc.Industry
NCT06564324 · 194 participants (planned) · Start Nov 27, 2024 · Primary completion Jan 2029
Drug: Taletrectinib; Crizotinib · For: Non Small Cell Lung Cancer
Sites: Hefei, China; Beijing, China; Chongqing, China · 29 sites in all
- Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)Pivotal-lookingRecruiting
Nuvation Bio Inc.Industry
NCT07154706 · 180 participants (planned) · Start Aug 21, 2025 · Primary completion Aug 30, 2030
Drug: Taletrectinib; Placebo · For: Non-small Cell Lung Cancer (NSCLC)
Sites: Los Angeles, California; Orange, California; Washington D.C., District of Columbia · 33 sites in all
Marketed drugs (1)
Newest FDA action first.
- Ibtrozi Taletrectinib Adipate · 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.